# Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis

> **NCT01078155** · — · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 131 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Osteoporosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01078155
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2015-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01078155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01078155, "Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01078155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*